

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Denning Chong
Date of last notice	27 February 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect (2) Indirect
Nature of indirect interest (including registered holder)	(1) JCC HEALTH PTY LTD <THE JDE MEDVR A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary (2) JDE CAPITAL PTY LTD <JDE CAPITAL A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary (consolidated disclosure from previous 3Y)
Date of change	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) 25 July 2024 (2.1) 25 July 2024 (2.2) N/A (2.3) N/A (2.4) N/A (2.5) N/A (2.6) 25 July 2024 (2.7) 25 July 2024

⁺ See [chapter 19](#) for defined terms.

No. of securities held prior to change	<p>(1.1) 4,640,869 - ORDINARY FULLY PAID SHARES</p> <p>(1.2) 4,500,000 - UNLISTED OPTIONS @ \$0.30</p> <p>(1.3) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.4) 1,200,000 - PERFORMANCE RIGHTS - CLASS B</p> <p>(1.5) NIL - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) 3,167,706 - ORDINARY FULLY PAID SHARES</p> <p>(2.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) 1,000,000 - PERFORMANCE RIGHTS - TRANCHE A</p> <p>(2.5) 500,000 - PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.6) 6,000,000 - PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.7) NIL - PERFORMANCE RIGHTS EXP 30/06/2028</p>
Class	<p>(1.1) ORDINARY FULLY PAID SHARES</p> <p>(1.2) UNLISTED OPTIONS @ \$0.30</p> <p>(1.3) UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.4) PERFORMANCE RIGHTS - CLASS B</p> <p>(1.5) PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) ORDINARY FULLY PAID SHARES</p> <p>(2.2) UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) PERFORMANCE RIGHTS - TRANCHE A</p> <p>(2.5) PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.6) PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.7) PERFORMANCE RIGHTS EXP 30/06/2028</p>

Number acquired	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (2.1) 1,500,000 - ORDINARY FULLY PAID SHARES (2.2) NIL (2.3) NIL (2.4) NIL (2.5) NIL (2.6) NIL (2.7) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028
Number disposed	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) NIL (2.1) NIL (2.2) NIL (2.3) NIL (2.4) NIL (2.5) NIL (2.6) (1,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027) (2.7) NIL

Value/Consideration	<p>(1.1) N/A</p> <p>(1.2) N/A</p> <p>(1.3) N/A</p> <p>(1.4) N/A</p> <p>(1.5) As set out in the Company's Notice of General Meeting lodged with ASX 21 May 2024.</p> <p>(2.1) Fully paid ordinary shares issued upon conversion of Performance Rights issued under the Company's Employee Securities Incentive Plan as previously approved by shareholders. Estimated value of consideration \$150,000</p> <p>(2.2) N/A</p> <p>(2.3) N/A</p> <p>(2.4) N/A</p> <p>(2.5) N/A</p> <p>(2.6) Refer 2.1 above.</p> <p>(2.7) As set out in the Company's Notice of General Meeting lodged with ASX 21 May 2024.</p>
No. of securities held after change	<p>(1.1) 4,640,869 - ORDINARY FULLY PAID SHARES</p> <p>(1.2) 4,500,000 - UNLISTED OPTIONS @ \$0.30</p> <p>(1.3) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.4) 1,200,000 - PERFORMANCE RIGHTS - CLASS B</p> <p>(1.5) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) 4,667,706 - ORDINARY FULLY PAID SHARES</p> <p>(2.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) 1,000,000 - PERFORMANCE RIGHTS - TRANCHE A</p> <p>(2.5) 500,000 - PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.6) 4,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.7) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p>

Nature of change	<p>(1.1) N/A</p> <p>(1.2) N/A</p> <p>(1.3) N/A</p> <p>(1.4) N/A</p> <p>(1.5) Allotment of Director performance rights as approved by the Company's shareholders at the General Meeting held 27 June 2024.</p> <p>(2.1) Conversion of performance rights</p> <p>(2.2) N/A</p> <p>(2.3) N/A</p> <p>(2.4) N/A</p> <p>(2.5) N/A</p> <p>(2.6) Conversion of performance rights</p> <p>(2.7) Allotment of Director performance rights as approved by the Company's shareholders at the General Meeting held 27 June 2024.</p>
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Howard Digby
Date of last notice	14 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect (2) Direct (3) Direct
Nature of indirect interest (including registered holder)	(1) LAMMA NOMINEES PTY LTD <XL MIDDLETON A/C>, an entity controlled by Mr Digby, of which he is a beneficiary (2) N/A (3) N/A
Date of change	(1) N/A (2.1) N/A (2.2) N/A (3) 25 July 2024
No. of securities held prior to change	(1) 35,000 - ORDINARY FULLY PAID SHARES (2.1) 1,000,000 - UNLISTED OPTIONS @ \$0.30 (2.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) 267,391 - ORDINARY FULLY PAID SHARES

⁺ See [chapter 19](#) for defined terms.

Class	(1) ORDINARY FULLY PAID SHARES (2.1) UNLISTED OPTIONS @ \$0.30 (2.2) UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) ORDINARY FULLY PAID SHARES
Number acquired	(1) NIL (2.1) NIL (2.2) NIL (3) 378,218 - ORDINARY FULLY PAID SHARES
Number disposed	(1) NIL (2.1) NIL (2.2) NIL (3) NIL
Value/Consideration	(1) N/A (2.1) N/A (2.2) N/A (3) Nil - Shares issued in lieu of Directors Fees otherwise payable in Cash. Estimated value of consideration \$37,443
No. of securities held after change	(1) 35,000 - ORDINARY FULLY PAID SHARES (2.1) 1,000,000 - UNLISTED OPTIONS @ \$0.30 (2.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) 645,609 - ORDINARY FULLY PAID SHARES
Nature of change	(1) N/A (2.1) N/A (2.2) N/A (3) Shares issued to Mr Digby in lieu of Directors Fees otherwise payable in Cash approved by Shareholders at the General Meeting of the Company held on 27 June 2024.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A

⁺ See [chapter 19](#) for defined terms.

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.
01/01/2011 Appendix 3Y Page 3

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Andrew Just
Date of last notice	14 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	(1) 25 July 2024 (2) N/A (3) N/A
No. of securities held prior to change	(1) NIL - ORDINARY FULLY PAID SHARES (2) 1,000,000 - UNLISTED OPTIONS @ \$0.30 (3) 1,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027
Class	(1) ORDINARY FULLY PAID SHARES (2) UNLISTED OPTIONS @ \$0.30 (3) UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027
Number acquired	(1) 336,364 - ORDINARY FULLY PAID SHARES (2) NIL (3) NIL
Number disposed	(1) NIL (2) NIL (3) NIL

⁺ See [chapter 19](#) for defined terms.

Value/Consideration	(1) Nil - Shares issued in lieu of Directors Fees otherwise payable in Cash. Estimated value of consideration \$33,300 (2) N/A (3) N/A
No. of securities held after change	(1) 336,364 - ORDINARY FULLY PAID SHARES (2) 1,000,000 - UNLISTED OPTIONS @ \$0.30 (3) 1,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027
Nature of change	(1) Shares issued to Mr Just in lieu of Directors Fees otherwise payable in Cash approved by Shareholders at the General Meeting of the Company held on 27 June 2024. (2) N/A (3) N/A

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.